Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of its next generation technology for dried blood spot (DBS) sample collection. The novel collection system combines Tasso’s new Tile™-T20 dried whole blood cartridge with a Tasso™ Mini device, enabling the precise, convenient collection of DBS samples for clinical trials and sports anti-doping testing.

Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, and ARUP Laboratories, the largest nonprofit clinical and academic reference laboratory in the United States, today announced that they have entered into a partnership to develop and operationalize high-quality, at-home, blood testing services to support clinical research.

InnoVero, a global leader in providing innovative, athlete-centric collection technologies to anti-doping organizations worldwide and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the extension of their partnership that was first initiated in 2021. In addition to collaboratively developing new athlete-centric solutions, InnoVero will continue to serve as the exclusive worldwide distributor of Tasso blood collection solutions for the anti-doping marketplace.

Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced a new collaboration that will reduce patient burden in clinical trials requiring blood collection. Lindus Health will adopt Tasso’s virtually painless remote blood collection technology as an option for sponsors looking to enable simple, more cost-effective remote blood collection while conducting their clinical trials. This innovative method will allow participants to collect simple blood samples themselves at home without the need for a mobile phlebotomist or nurse.

The Leukemia & Lymphoma Society® (LLS), a global leader in the fight against blood cancer, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced a collaboration to accelerate blood cancer research. The relationship will combine Tasso’s signature capillary blood collection technology with LLS’ research and focus on patient advocacy, with the goal of improving the oncology patient experience.

The Parkinson’s Foundation and Tasso, Inc. today announced a partnership to expand and accelerate genetic research into Parkinson’s disease (PD). The partnership leverages Tasso’s patient-centric, end-to-end sample collection and logistics platform to enable data collection for a landmark international genetics study by the Parkinson’s Foundation: PD GENEration: Mapping the Future of Parkinson’s.

Last week we accomplished a huge milestone and shipped our one millionth device. This was an incredible moment for our company as a whole and something that was hard to imagine when we first started out nearly 12 years ago.

Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of Tasso Care® for Prescreening, an end-to-end services solution to maximize the success of a prescreening program. The new offering expands the foundation and expertise of the Tasso Care services platform in remote blood collection and analysis to support clinical trial recruitment.

In 2023, Tasso achieved remarkable growth driven by our unwavering focus on expanding access to care for more patients by offering convenient diagnostic healthcare options. Our patient-centric blood collection solutions have proven to be a valuable addition to the pharmaceutical and healthcare industry. Several new engagements forged in the second half of 2023 support our continued growth and ability to offer more complete solutions to the industry.

Randox Health, which provides at-home and in-clinic health tests as part of Randox – the largest healthcare diagnostics company in the UK and Ireland – and Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced a partnership to offer at-home healthcare diagnostic testing powered by Tasso’s innovative blood collection technology.

Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the successful completion of the System and Organization Controls (SOC) 2 Type 2 audit. The SOC 2 Type 2 audit is conducted by independent auditors to determine whether a company is maintaining a high standard for handling sensitive client data through its operations, controls, and processes. The auditors observed Tasso’s operations against all five SOC 2 Trust Services Criteria (Security, Availability, Processing Integrity, Confidentiality, and Privacy) and found no exceptions. This achievement demonstrates Tasso’s ability to securely manage client data and highlights the company’s commitment to meeting the highest industry standards.

Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the appointment of Monica Williams as Chief Financial Officer, reporting to Tasso’s CEO Ben Casavant.

Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced it received CE Mark certification for its Tasso+™ device, a convenient, virtually pain-free blood lancet that collects whole liquid blood samples. The CE Mark designation allows Tasso to offer its patient-centric, high-volume blood collection solution in the European Union (EU) market, which includes 28 member states, plus Iceland, Norway and Lichtenstein. The CE Mark designation ensures a product has met all European Commission safety, health and environmental protection requirements.